Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (JIL) Price & Analysis

2 Followers

JIL Stock Chart & Stats

€0.23

Market closed

€0.23

Day’s Range― - ―

52-Week Range€0.21 - €0.31

Previous CloseN/A

VolumeN/A

Average Volume (3M)125.00

Market Cap

€173.30M

Enterprise Value€245.91M

Total Cash (Recent Filing)€902.41M

Total Debt (Recent Filing)€399.93K

Price to Earnings (P/E)4.6

Beta0.03

Next Earnings

Apr 01, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.50

Shares Outstanding172,500,000

10 Day Avg. Volume375

30 Day Avg. Volume125

Financial Highlights & Ratios

PEG Ratio0.92

Price to Book (P/B)0.65

Price to Sales (P/S)1.22

P/FCF Ratio3.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Sustained ProfitabilityConsistently high gross and net margins indicate that the company has maintained strong economics across multiple years. Stable operating profitability provides resilience against moderate pressure and supports reinvestment, shareholder returns, and continued operation through changing industry conditions.

Conservative Balance SheetLow leverage and a growing equity base give the company meaningful financial flexibility. This conservative capital structure can reduce the burden of interest and refinancing obligations, helping preserve capacity to fund products, operations, and strategic priorities over the coming quarters.

Strong Cash GenerationFree cash flow that broadly tracks net income suggests reported profitability is converting into usable cash. The strong 2025 level improves the company’s ability to fund internal needs, maintain financial resilience, and support capital allocation without relying heavily on additional borrowing.

Bears Say

Cooling Revenue MomentumThe recent progression from strong earlier expansion to flat, modest, and then slightly negative revenue growth signals weaker top-line momentum. If this persists, it could limit operating leverage, reduce the pace of earnings expansion, and make future growth increasingly dependent on profitability discipline.

Volatile Cash ConversionAlthough recent cash generation is strong, the sizable year-to-year swings show that cash conversion has not been consistently stable. Such variability can complicate budgeting and capital allocation, particularly if weaker cash-flow periods recur while revenue growth remains subdued.

Recent Debt IncreaseThe increase in debt during 2023–2024 is a structural change in the funding profile, even though leverage remains manageable. Continued borrowing could raise interest and refinancing exposure, reduce balance-sheet flexibility, and weaken one of the company’s current financial advantages.

JIL FAQ

What was Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price range in the past 12 months?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H lowest stock price was €0.21 and its highest was €0.31 in the past 12 months.

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s market cap is €173.30M.

When is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 155 days.

How were Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s earnings last quarter?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H released its earnings results on Aug 14, 2026. The company reported €0.028 earnings per share for the quarter.

Is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H overvalued?

According to Wall Street analysts Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H pay dividends?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H does not currently pay dividends.

What is Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H have?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has 172,500,000 shares outstanding.

What happened to Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H’s price movement after its last earnings report?

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H reported an EPS of €0.028 in its last earnings report. Following the earnings report the stock price went down -4.839%.

Which hedge fund is a major shareholder of Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H?

Currently, no hedge funds are holding shares in DE:JIL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H

Jilin Province Huinan Changlong Bio-pharmacy Company Limited focuses on the manufacturing and sale of traditional Chinese medicines and various pharmaceutical products within the People's Republic of China. The company's extensive product portfolio includes a wide range of dosage forms such as tablets, capsules, and pills, as well as specialized items like Chinese medicine pretreatment and extraction products. They also provide various injectable solutions, including powders for injection, lyophilized powders for injection, and small volume liquid injections, along with active pharmaceutical ingredients (APIs) and granules. These products are primarily sold under the "Changlong" and "Qing Tong" brand names. Established in 1989, and headquartered in Kowloon, Hong Kong, the company was previously known as Jilin Province Huinan Biochemical Pharmaceutical Company Limited.